Cargando…

Hematological Malignancies and HBV Reactivation Risk: Suggestions for Clinical Management

It is well known that hepatitis B virus reactivation (HBVr) can occur among patients undergoing treatment for hematological malignancies (HM). The evaluation of HBVr risk in patients undergoing immunosuppressive treatments is a multidimensional process, which includes conducting an accurate clinical...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zannella, Alessandra, Marignani, Massimo, Begini, Paola
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6784078/ https://www.ncbi.nlm.nih.gov/pubmed/31540124 http://dx.doi.org/10.3390/v11090858

Ejemplares similares

Glucocorticoids and Antivirals for HBV Reactivation in Onco-Hematologic Patients.
por: Marzano, Alfredo, et al.
Publicado: (2010)

COVID-19 emergency: Changes in quality of life perception in patients with chronic liver disease-An Italian single-centre study
por: Zannella, Alessandra, et al.
Publicado: (2022)

Hepatitis B in patients with hematological diseases: An update
por: Coluccio, Chiara, et al.
Publicado: (2017)

HDV+HBV hepatitis reactivation due to immunossuppressive therapy for hematological malignancies – an increasingly complex challenge
por: Molagic, Violeta, et al.
Publicado: (2013)

Prevention of HBV Reactivation in Hemato-Oncologic Setting during COVID-19
por: Sagnelli, Caterina, et al.
Publicado: (2022)

Prevention and management of hepatitis B virus reactivation in patients with hematological malignancies in the targeted therapy era
por: Mak, Joyce Wing Yan, et al.
Publicado: (2023)

Risk Factors for Liver Decompensation and HCC in HCV-Cirrhotic Patients after DAAs: A Multicenter Prospective Study
por: Morisco, Filomena, et al.
Publicado: (2021)

Rituximab Administration and Reactivation of HBV
por: Tsutsumi, Yutaka, et al.
Publicado: (2010)

HBV-HCV Coinfection: Viral Interactions, Management, and Viral Reactivation
por: Mavilia, Marianna G., et al.
Publicado: (2018)

Assessment and Management of Cardiotoxicity in Hematologic Malignancies
por: Bojan, Anca, et al.
Publicado: (2021)

Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies
por: Perpinia, Anastasia Stella, et al.
Publicado: (2022)

MDM2/X inhibitors under clinical evaluation: perspectives for the management of hematological malignancies and pediatric cancer
por: Tisato, Veronica, et al.
Publicado: (2017)

Prophylaxis of hepatitis B virus (HBV) infection reactivation – recommendations of the Working Group for prevention of HBV reactivation
por: Pawłowska, Małgorzata, et al.
Publicado: (2019)

A Hyper-Glycosylation of HBV Surface Antigen Correlates with HBsAg-Negativity at Immunosuppression-Driven HBV Reactivation in Vivo and Hinders HBsAg Recognition In Vitro
por: Salpini, Romina, et al.
Publicado: (2020)

Recognizing and managing the expanded risk of tumor lysis syndrome in hematologic and solid malignancies
por: McBride, Ali, et al.
Publicado: (2012)

Recent Advances in HBV Reactivation Research
por: Guo, Lixia, et al.
Publicado: (2018)

Approaches to Managing Safety With Lenalidomide in Hematologic Malignancies
por: Blumel, Susan, et al.
Publicado: (2014)

Management of Venous Thromboembolism for Patients With Hematologic Malignancies
por: Schwartz, Rowena N.
Publicado: (2017)

Syk inhibitors in clinical development for hematological malignancies
por: Liu, Delong, et al.
Publicado: (2017)

Deubiquitinases in hematological malignancies
por: Lei, Hu, et al.
Publicado: (2021)

Autophagy in Hematological Malignancies
por: García Ruiz, Olga, et al.
Publicado: (2022)

COVID-19 as Another Trigger for HBV Reactivation: Clinical Case and Review of Literature
por: Sagnelli, Caterina, et al.
Publicado: (2022)

COT-06 HBV REACTIVATION DURING AND AFTER THE TREATMENT OF MALIGNANT GLIOMA WITH TEMOZOLOMIDE
por: Kanamori, Masayuki, et al.
Publicado: (2019)

Management strategy for hematological malignancy patients with acute respiratory failure
por: Jiang, Li, et al.
Publicado: (2021)

Exosome-Mediated Therapeutic Strategies for Management of Solid and Hematological Malignancies
por: Allegra, Alessandro, et al.
Publicado: (2022)

Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies
por: Tian, Zheng, et al.
Publicado: (2021)

Sarcopenia Diagnosis and Management in Hematological Malignancies and Differences with Cachexia and Frailty
por: Colloca, Giuseppe Ferdinando, et al.
Publicado: (2023)

Hepatocellular Carcinoma Drug-Eluting Bead Transarterial Chemoembolization (DEB-TACE): Outcome Analysis Using a Model Based On Pre-Treatment CT Texture Features
por: Tipaldi, Marcello Andrea, et al.
Publicado: (2021)

Histone deacetylase inhibitors: clinical implications for hematological malignancies
por: Tambaro, Francesco Paolo, et al.
Publicado: (2010)

Clinical trials with anti-angiogenic agents in hematological malignancies
por: Medinger, Michael, et al.
Publicado: (2010)

The functions and clinical significance of circRNAs in hematological malignancies
por: Zhou, Xiangxiang, et al.
Publicado: (2020)

Metabolic Reprogramming in Hematologic Malignancies: Advances and Clinical Perspectives
por: Yu, Zhuoya, et al.
Publicado: (2022)

Notch signaling: its roles and therapeutic potential in hematological malignancies
por: Gu, Yisu, et al.
Publicado: (2016)

Consensus Recommendations for the Clinical Management of Hematological Malignancies in Patients with DNA Double Stranded Break Disorders
por: Pastorczak, Agata, et al.
Publicado: (2022)

Vorinostat in solid and hematologic malignancies
por: Siegel, David, et al.
Publicado: (2009)

The treatment of hematologic malignancies in pregnancy
por: Vandenbriele, C., et al.
Publicado: (2010)

Telomerase Activation in Hematological Malignancies
por: Ropio, Joana, et al.
Publicado: (2016)

Epigenetics of hematopoiesis and hematological malignancies
por: Hu, Deqing, et al.
Publicado: (2016)

Rac GTPases in Hematological Malignancies
por: Durand-Onaylı, Valerie, et al.
Publicado: (2018)

Arterial stiffness in hematologic malignancies
por: Mozos, Ioana, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_q6a17hj6v9rlk428cnvc43f9gd